GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaEngine Inc (ROCO:4162) » Definitions » Buyback Yield %

PharmaEngine (ROCO:4162) Buyback Yield % : 0.00 (As of Apr. 30, 2025)


View and export this data going back to 2012. Start your Free Trial

What is PharmaEngine Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

PharmaEngine's current buyback yield was 0.00%.


PharmaEngine Buyback Yield % Historical Data

The historical data trend for PharmaEngine's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaEngine Buyback Yield % Chart

PharmaEngine Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 1.28 - - -

PharmaEngine Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PharmaEngine's Buyback Yield %

For the Biotechnology subindustry, PharmaEngine's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaEngine's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaEngine's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where PharmaEngine's Buyback Yield % falls into.


;
;

PharmaEngine Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

PharmaEngine's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 12974.1234
=0.00%

PharmaEngine's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 12974.1234
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .


PharmaEngine Buyback Yield % Related Terms

Thank you for viewing the detailed overview of PharmaEngine's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaEngine Business Description

Traded in Other Exchanges
N/A
Address
10 Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its projects pipeline are: ONIVYDE was approved by the U.S. FDA, Taiwan FDA, and EMA for patients with gemcitabine-treated metastatic pancreatic cancer; and PEP07. It generates the revenue from Sales of goods.

PharmaEngine Headlines

No Headlines